Avastin and Lucentis are Equivalent in Treating AMD: CATT Two-Year Results
In July 2012, Ophthalmology published the final results from the two-year Comparison of Age-related Macular Degeneration Treatments Trials (CATT) clinical trial comparing Lucentis and Avastin treatments for wet age-related macular degeneration (AMD).
July 13, 2012
Lay summary: Acquired pseudoxanthoma elasticum after liver transplant
Recently researchers examined three cases involving young women who acquired PXE after liver transplants, even though they previously had no detectable signs or symptoms of the disease.
November 18, 2011
Interview with Karobi Moitra, Ms, PhD, Analyzing the genomes of PXEers
Dr. Moitra works with Mike Dean at the National Cancer Institute analyzing the genomes of patients who suffer from pseudoxanthoma elasticum.
November 18, 2011
Monthly Lucentis - Safe and Effective for PXE?
Report on a 12-month, open-label, uncontrolled, non-randomized study on the use of Lucentis in patients with pseudoxanthoma elasticum and active CNV.
October 28, 2011
Rescue of ABCC6 Disease-Causing Mutations in Mouse Liver
In a very complex experiment, a team of PXE researchers led by Dr. Váradi and Dr. Le Saux were able to rescue some function in an ABCC6 gene with disease-causing mutations in a live mouse liver. This news is very exciting and may have some application to a future therapy for pseudoxanthoma elasticum in humans.
October 12, 2011
Lay Summary: The Effects of Pseudoxanthoma Elasticum (PXE) on the Placenta and Pregnancy
Early literature on pregnancy in women with pseudoxanthoma elasticum [PXE] contained reports of severe complications. However, more recent studies do not support that recommendation and to date, there is no strong evidence linking PXE to complications during pregnancy for the mother or the fetus.